KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Goodwill: 2020-2025

Historic Goodwill for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $162.0 million.

  • Recursion Pharmaceuticals' Goodwill rose 211.28% to $162.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.0 million, marking a year-over-year increase of 211.28%. This contributed to the annual value of $148.9 million for FY2024, which is 185.99% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Goodwill stood at $162.0 million, which was down 1.36% from $164.3 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Goodwill registered a high of $164.3 million during Q2 2025, and its lowest value of $801,000 during Q1 2021.
  • Moreover, its 3-year median value for Goodwill was $52.8 million (2023), whereas its average is $86.9 million.
  • Its Goodwill has fluctuated over the past 5 years, first surged by 7,455.06% in 2023, then decreased by 13.98% in 2024.
  • Recursion Pharmaceuticals' Goodwill (Quarterly) stood at $801,000 in 2021, then remained steady at $801,000 in 2022, then skyrocketed by 6,398.88% to $52.1 million in 2023, then spiked by 185.99% to $148.9 million in 2024, then skyrocketed by 211.28% to $162.0 million in 2025.
  • Its last three reported values are $162.0 million in Q3 2025, $164.3 million for Q2 2025, and $158.1 million during Q1 2025.